Skip to main content
Premium Trial:

Request an Annual Quote

Bruker to Supply Sequenom with Mass Spectrometer for New MassArray System

NEW YORK, Nov. 5 – Bruker Daltonics has agreed to develop a bench-top mass spectrometer to be integrated into a new Sequenom MassArray genotyping system for medium throughput analysis, the companies said Monday.

Under the terms of the deal Bruker Daltonics will develop a new GenoFlex system based on MALDI-TOF mass spectrometry. Sequenom currently uses a similar Bruker-based platform for its high-throughput MassArray system. 

The companies did not disclose the financial terms or the deal or how much the new system would cost. The company has said previously that a high-throughput MassArray system costs between $400,000 and $1.1 million, depending on consumables. 

Sequenom of San Diego said that it hoped the new system would help it to expand its customer base.

“We expect the addition of the GenoFlex MT to provide Sequenom with access to a broader market segment of customers which may be in the earlier stages of their ramp up in throughput requirements for genotyping, but are still interested in the features of our MassArray product line," Sequenom’s CEO Toni Schuh said in a statement. 

Last week, Bruker Daltonics of Billerica, Mass., announced that it had agreed to work with Swedish proteomics company Biacore to develop a new proteomics system that would combine Biacore’s surface plasmon resonance technology with Bruker Daltonics mass spectrometry capabilities in a new platform to be known as SPR-MS. 

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.